TP53 and gastrointestinal stromal tumor: In addition, future studies may explore the combination of adavosertib and sunitinib using GIST882 and GIST-T1 cells, both of which harbor mutant p53 and are sensitive to sunitinib [59,60], to evaluate synergistic effects in distinct genetic contexts.